Hans Baumeister
- Co-authors
- Dietmar RichterWolfgang MeyerhofDieter MüllerSabine Krüger‐KrasagakesPia WelkerBeate M. HenzUndine LippertAndreas Grützkau
- Topics
- Monoclonal and Polyclonal Antibodies Research (9 papers)HER2/EGFR in Cancer Research (6 papers)Glycosylation and Glycoproteins Research (5 papers)
- Partner nations
- GermanyItalySwitzerland
In The Last Decade
Hans Baumeister
24 papers receiving 750 citations
Peers
Comparison fields: 5 of 86
- Molecular Biology 359
- Immunology 232
- Epidemiology 139
- Oncology 132
- Physiology 111
Countries citing papers authored by Hans Baumeister
This map shows the geographic impact of Hans Baumeister's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Baumeister with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Baumeister more than expected).
Fields of papers citing papers by Hans Baumeister
This network shows the impact of papers produced by Hans Baumeister. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Baumeister. The network helps show where Hans Baumeister may publish in the future.
Co-authorship network of co-authors of Hans Baumeister
This figure shows the co-authorship network connecting the top 25 collaborators of Hans Baumeister. A scholar is included among the top collaborators of Hans Baumeister based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Baumeister. Hans Baumeister is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 14 | |
| 2 | 12 | |
| 3 | 1 | |
| 4 | 1 | |
| 5 | GlycoOptimization for Fully Human and Largely Improved Biopharmaceutical Antibodies and Proteins | 2 |
| 6 | 52 | |
| 7 | In vitro priming of tumor-specific cytotoxic T lymphocytes from healthy donors using allogeneic dendritic cells derived from the MUTZ-3 cell line (NMDC) | 1 |
| 8 | 3 | |
| 9 | 18 | |
| 10 | 9 | |
| 11 | 14 | |
| 12 | 76 | |
| 13 | 32 | |
| 14 | 275 | |
| 15 | 37 | |
| 16 | 40 | |
| 17 | 64 | |
| 18 | 23 | |
| 19 | 25 | |
| 20 | 65 |
About Hans Baumeister
Hans Baumeister is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Genetics, having authored 24 papers that have together received 774 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (9 papers), HER2/EGFR in Cancer Research (6 papers) and Glycosylation and Glycoproteins Research (5 papers). The work is most often cited by research in Immunology (232 citations), Immunology and Allergy (51 citations) and Endocrinology, Diabetes and Metabolism (107 citations). Hans Baumeister has collaborated with scholars based in Germany, Italy and Switzerland. Frequent co-authors include Dietmar Richter, Wolfgang Meyerhof, Dieter Müller, Sabine Krüger‐Krasagakes, Pia Welker, Beate M. Henz, Undine Lippert, Andreas Grützkau, Constanze Schwarz and Annelie Möller. Their work appears in journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.